VectorXcellerator Programme: Fully funded feasibility studies to support early-stage cell and gene therapy programmes

Webinar: Optimising viral vector manufacturing with CDMO expertise and innovation

News: OXB honoured at 2025 CDMO Leadership Awards Europe in ‘Cell & Gene Therapy’ category

Hsp40 Molecules That Target to the Ubiquitin-proteasome System Decrease Inclusion Formation in Models of Polyglutamine Disease

September 17, 2024